C. Garay

发表

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.

J. Berlin, A. Oza, J. Marshall, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.

A. Benson, N. Kemeny, H. Hochster, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus weekly gemcitabine (Gem) in patients (pts) with advanced solid tumors: preliminary results

M. Korc, A. Patnaik, L. Rosen, 2008 .

Phase I, multicenter trial of CNTO 328, an anti-interleukin(IL)-6 monoclonal antibody (mAb) in subjects with selected hematologic malignancies.

R. Kurzrock, H. Borghaei, R. Orlowski, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer.

G. Hudes, B. Roth, James F. Babb, 2001, Urology.

Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck.

D. Shin, A. Colevas, M. Posner, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Coexisting myelodysplasia and myeloproliferative features in a single clone containing 5q-, Ph and i(17q).

J. Testa, T. Al-Saleem, M. Smith, 1999, Leukemia research.

Chemoprevention of colorectal cancer: dietary and pharmacologic approaches.

P. Engstrom, C. Garay, G. Ca, 1999, Oncology.

Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.

W. Miller, D. Haller, G. Bodoky, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selecting renal cell carcinoma therapy: Ranking of patient perspective on toxicities.

A. Hauber, A. Mohamed, M. Wong, 2012 .

Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma

A. Hauber, A. Mohamed, M. Wong, 2012, Journal of medical economics.

Original article Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma

A. Hauber, A. Mohamed, M. Wong, 2012 .

CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb) - Preliminary Results of Subjects with Castleman’s Disease from a Phase 1 Study in Selected Hematological Malignancies.

R. Kurzrock, H. Borghaei, R. Orlowski, 2006 .

Safety and efficacy of everolimus in patients with non-clear cell renal cell carcinoma refractory to VEGF-targeted therapy: Subgroup analysis of REACT.

C. Blank, V. Grünwald, P. Bono, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of everolimus in patients with non-clear cell renal cell carcinoma refractory to VEGF-targeted therapy: Subgroup analysis of REACT.

C. Blank, V. Grünwald, P. Bono, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.